Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. ChemoCentryx's lead independent drug candidate, CCX140-B, a CCR2 antagonist, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetes. CCX140-B is expected to enter Phase II clinical development for the treatment of diabetic nephropathy in 2011. Other clinical programs include CCX354, a CCR1 antagonist which recently completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, in Phase II clinical development for the treatment of vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy o
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ended ... a 10 percent increase compared to the quarter ended December ... basis). Net income was $91.2 million, an increase of 5 ... earnings per share for the quarter were $0.64, an increase ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... of cancer. Cells without this protein are usually rendered genetically ... it from growing. However sometimes mutations alter cells in such ... Researchers indicated that loss of E2F3 itself doesn't cause cancer ... change into a cancer cell.// E2F3 is part of a ...
... indicates that Negative exercise electrocardiograph tests should ... of hypertensive patients with chest pain. Even ... risk, positive findings could not distinguish levels ... pharmacological stress echocardiography yielded diagnostic and prognostic ...
... SARS patients in India went up to 10, authorities are ... India has shown a far higher recovery rate than the ... and superior medical care provided to SARS patients. Even what ... and they are only between 60 and 65 per cent ...
... With a severe blow by SARS, the economies of ... quarter. More than five million foreign workers, from Filipina ... the wheels of commerce in the region, sending home ... families. Studies show most of those families used the ...
... victims have been refused treatment in Indian clinics where ... have been moved to government hospital. Private medical centre ... SARS infected patients. The patients include a bride, her ... the ceremony from Indonesia via Singapore. There were also ...
... SARS on a plane trip may probably be small if ... too little is currently known about the virus. However people ... strong filters against viruses. There have even been policies implemented ... equipped with sophisticated air cleaning systems that has stringent filters ...
Cached Medicine News:
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
... intended for monitoring the accuracy and precision of ... in vitro diagnostic use only. Provided in a ... up to ten days stability at 2 ... used in accordance with the directions accompanying the ...
PowerMed is a billing software....
Managed care is a billing and tracking system....
Medicine Products: